Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
November 05, 2024 08:00 ET | Insignis Therapeutics, Inc.
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
October 07, 2024 08:00 ET | Insignis Therapeutics, Inc.
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.